- •Corneal Disease
- •Preface
- •Contents
- •Contributors
- •Core Messages
- •Organisms
- •Detection
- •Acid Fast Smears
- •Culture Media
- •Molecular Tests
- •Nucleic Acid Hybridization Probes
- •Line Probes
- •DNA Sequencing
- •FISH (Fluorescent In Situ Hybridization) Assay
- •DNA Microarray
- •Pulse Field Gel Electrophoresis (PFGE)
- •Management
- •Clinical Diagnosis
- •Medical Therapy
- •Surgical Intervention
- •Penetrating Keratoplasty
- •Corneal Cross-Linking
- •Summary for the Clinician
- •References
- •Core Messages
- •Introduction
- •Epidemiology
- •Visual Morbidity
- •Documentation
- •Causative Factors
- •Causative Bacteria
- •Investigation of Keratitis
- •Laboratory Diagnosis: Susceptibility Testing
- •Susceptibility and Resistance of Bacterial Isolates
- •Treatment: Antimicrobials
- •Current Antimicrobials in Use
- •The Fluoroquinolones
- •Aminoglycosides
- •Cephalosporins
- •Other Antimicrobials Used
- •Development of Existing and New Classes of Drugs
- •Tigecycline
- •Linezolid
- •Meropenem
- •Combination Therapy
- •Drug Delivery to the Cornea
- •Novel Methods of Drug Delivery to the Cornea
- •Conclusion
- •References
- •3: Heredity of Keratoconus
- •Introduction
- •Is Keratoconus a Heritable or Genetic Disease?
- •Mutational Screening of Candidate Genes in Keratoconus
- •Visual System Homeobox Gene 1 (VSX1)
- •Superoxide Dismutase 1 (SOD1)
- •Interleukin 1 (IL1) Superfamily
- •Collagen Genes
- •Genetic Mapping in Keratoconus
- •Genetics of Keratoconus – Mendelian or Complex?
- •References
- •4: Advance in Corneal Imaging
- •Introduction
- •In Vivo Confocal Microscopy (IVCM)
- •Principles of Confocal Microscopy
- •The Normal Cornea
- •Clinical Applications
- •Infectious Keratitis
- •Corneal Dystrophies
- •Refractive Surgery
- •Corneal Surgery
- •Other Clinical Applications
- •Limitations of IVCM
- •Anterior Segment Ocular Coherence Tomography (OCT)
- •Clinical Applications
- •Corneal Thickness Assessment
- •Refractive Surgery
- •Corneal Grafts
- •Limitations
- •Conclusion
- •References
- •Core Messages
- •Introduction
- •“Angiogenic Privilege of the Cornea” or “How Does the Normal Corneal Maintain Its Avascularity?”
- •General Mechanisms
- •Corneal Hemangiogenesis After Low-Risk Keratoplasty
- •Corneal Hemangiogenesis After High-Risk Keratoplasty
- •Corneal Lymphangiogenesis: Essential for Corneal Graft Rejection
- •Corneal Lymphangiogenesis in Dry Eye
- •Imaging of Corneal Lymphatic Vessels
- •Novel Anti(lymph)Angiogenic Treatment Options at the Cornea
- •Current Treatment Options for Immature Corneal (Blood and Lymphatic) Vessels
- •Steroids
- •Anti-VEGFs (Bevazicumab, Ranibuzumab, Pegaptanib, VEGF Trap)
- •Anti-IRS 1-Strategies (Antisense Oligonucleotides Against IRS 1)
- •Treatment Options for Mature Corneal Vessels
- •Unmet Needs and Future Directions
- •References
- •Core Messages
- •Introduction
- •Retrieval of Donor Tissue
- •Technical Aspects
- •Microbiological Aspects
- •Tissue Evaluation Aspects
- •Corneal Storage
- •Moist Chamber Storage of the Donor Eye
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Hypothermic Storage of the Corneoscleral Button
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Organ Culture (Normothermic Storage) of the Corneoscleral Button
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Other Aspects
- •Pre-cutting of Corneal Tissue for Endothelial Keratoplasty (EK)
- •Microkeratome Cutting
- •Femtosecond Laser Cutting
- •Stripping of Descemet’s Membrane with Endothelium
- •Donor Considerations for EK
- •References
- •7: Infant Keratoplasty
- •Core Messages
- •Introduction
- •Indications for Surgery
- •Visual Outcome
- •Patient Selection
- •Patient Assessment
- •Ancillary Testing
- •Donor Tissue
- •Intraoperative Considerations
- •Concurrent Surgical Procedures
- •Postoperative Considerations
- •Suture Management
- •Optical Correction and Amblyopia Therapy
- •Postoperative Complications
- •Glaucoma
- •Graft Rejection
- •Graft Failure
- •Alternatives to Penetrating Keratoplasty
- •Conclusion
- •References
- •Index
5 Antiangiogenic Treatment Options in the Cornea |
81 |
|
|
Fig. 5.3 In vivo imaging of corneal lymphatic vessels in a pathologically vascularized murine cornea using in vivo confocal microscopy. The HRT II with the Rostock cornea module shows black, empty appearing, and nearly cell-free lymphatic vessels (arrow) next to smaller, erythrocyte-filled blood vessels (arrowhead)
Imaging of Corneal Lymphatic Vessels
Lymphatic vessels in the cornea are not visible using slit-lamp magnification. That is due to their lumen being nearly free of cells and their absent basement membrane thus given too low contrast to surrounding extracellular matrix. Nonetheless, in recent years, new technologies have been developed to visualize corneal lymphatics:
(a)In vivo confocal microscopy using the HRT II and the Rostock cornea module: Using that approach, we and others were able to visualize lymphatic vessels in rodent corneas. The empty appearing, dark, and cell-free lymphatics could be identified by injection of dyes and subsequent immunohistochemistry. That approach should in the future also be applicable to patients in the clinic (Fig. 5.3).
(b)In vivo multiphoton imaging: This even more precise approach allows for unequivocal identification of immunohistochemically labeled lymphatics in the living cornea [35].
Based on the great advances in imaging lymphatics in vivo in animal models, it is likely that in the near future, visualization of lymphatics also in human corneas in the clinic will be possible. That would allow for precise risk assessment prior to keratoplasty by analyzing whether a vascularized high-risk cornea does contain lymphatic vessels in addition or not.
